Extended Access of Momelotinib in Adults With Myelofibrosis

Running, not enrolling · Phase 2

Conditions studied: Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis

In brief

The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101 (NCT01969838), GS-US-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746), SRA-MMB-301 who are currently receiving treatment with MMB (available as 50mg,100 mg, 150 mg and 200 mg tablets) and have not experienced progression of disease. The secondary objective is to assess overall survival (OS) and leukemia free survival (LFS) in all subjects.

Key facts

Study ID

NCT03441113

Run by

GlaxoSmithKline

People needed

237

Starts

2018-05-03

Expected to finish

2026-12-11

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• GSK Investigational Site — Orange, California, United States
• GSK Investigational Site — Stanford, California, United States
• GSK Investigational Site — Aurora, Colorado, United States
• GSK Investigational Site — Jacksonville, Florida, United States
• GSK Investigational Site — Tampa, Florida, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — Baltimore, Maryland, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — Rochester, Minnesota, United States
• GSK Investigational Site — St Louis, Missouri, United States
• GSK Investigational Site — Hackensack, New Jersey, United States
• GSK Investigational Site — The Bronx, New York, United States
• GSK Investigational Site — Cleveland, Ohio, United States
• GSK Investigational Site — South Brisbane, Queensland, Australia
• GSK Investigational Site — Bedford Park, South Australia, Australia
• GSK Investigational Site — Frankston, Victoria, Australia
• GSK Investigational Site — Melbourne, Victoria, Australia
• GSK Investigational Site — Melbourne, Victoria, Australia
• GSK Investigational Site — Perth, Western Australia, Australia
• GSK Investigational Site — Linz, Austria
• GSK Investigational Site — Vienna, Austria
• GSK Investigational Site — Antwerp, Belgium
• GSK Investigational Site — Bruges, Belgium
• GSK Investigational Site — Leuven, Belgium
• GSK Investigational Site — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.